Anixa Biosciences Inc (Anixa) is a biotechnology company. The company develops and acquires patented technologies in the areas such as cancer diagnostics, encrypted communications and semiconductor fabrication. It also develops non-invasive blood tests for the early detection of solid tumor-based cancers. The company primarily focuses on developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs and a COVID-19 therapeutics program on inhibiting certain viral protein functions. Anixa’s key therapeutics programs include breast cancer and ovarian cancer. It also involves in examining emerging technologies in complementary fields for future development and commercialization. Anixa is headquartered in San Jose, California, the US.
Anixa Biosciences Inc premium industry data and analytics
Products and Services
Products |
---|
Non-Invasive Blood Tests |
Anti Viral Products |
Cancer Vaccines |
XYZ |
XYZ |
XYZ |
Competitor Comparison
Key Parameters | Anixa Biosciences Inc | Legend Biotech Corp | Tango Therapeutics Inc | Notable Labs Ltd | Axcella Health Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | San Jose | Somerset | Boston | Foster City | Cambridge |
State/Province | California | New Jersey | Massachusetts | California | Massachusetts |
No. of Employees | 4 | 1,800 | 140 | 16 | 11 |
Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Amit Kumar | President; Chairman; Chief Executive Officer | Executive Board | 2017 | 59 |
Michael J Catelani | Chief Financial Officer; Chief Operating Officer; President | Senior Management | 2016 | 57 |
Pamela D. Garzone | Chief Development Officer | Senior Management | 2021 | - |
Emily Gottschalk | Director | Non Executive Board | 2019 | 63 |
Lewis H Titterton | Director | Non Executive Board | 2018 | 79 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer